Previous close | 16.77 |
Open | 17.39 |
Bid | 14.60 x 1100 |
Ask | 16.50 x 800 |
Day's range | 16.51 - 17.39 |
52-week range | 6.40 - 18.91 |
Volume | |
Avg. volume | 12,785 |
Market cap | 89.107M |
Beta (5Y monthly) | 1.51 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.86 |
Earnings date | N/A |
Forward dividend & yield | 2.34 (13.98%) |
Ex-dividend date | 14 Mar 2024 |
1y target est | N/A |
Record consolidated net revenue of $84.5 million for full-year 2023 Fortress may receive up to four regulatory decisions on NDAs and BLAs in the next 18 months FDA accepted New Drug Application filing for DFD-29 to treat inflammatory lesions and erythema of rosacea in adults; PDUFA goal date of November 4, 2024 MIAMI, March 28, 2024 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance
Planning for proof-of concept Phase 1 investigator-sponsored clinical trial evaluating MB-106 CD20-targeted CAR T-cell therapy in autoimmune diseases is underway and expected to initiate in the fourth quarter of 2024 MB-106 data in B-cell non-Hodgkin lymphoma (NHL) provide a strong foundation for future development in autoimmune disease; pivotal trial for Waldenstrom macroglobulinemia (WM) is expected to initiate in the second half of 2024 WORCESTER, Mass., March 28, 2024 (GLOBE NEWSWIRE) -- Mus
MIAMI, March 25, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that it will host a virtual key opinion leader (“KOL”) event highlighting expert perspectives on spinal bulbar muscular atrophy (“SBMA”), also known as Kennedy's Disease, on Thursday, April 4, 2024 at 11:00am ET. The virtual event wi